inflammation/phosphatase

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 24 rezilta yo

Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The current invention relates to the field of medicine and in particular to the use of LPS detoxifying and neutralizing enzymes. The present invention also relates to the field of pharmacy and in particular to the pharmaceutical use of alkaline phosphatase enzymes. BACKGROUND

Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This invention relates to a method of inhibiting Protein Tyrosine Phosphatase 1B (PTP1B) and/or T-cell Protein Tyrosine Phosphatase (TC-PTP) and/or Protein Tyrosine Phosphatases (PTPases) having an aspartic acid (Asp) in position 48 (PTP1B numbering, Chernoff et al., Proc.

Protein tyrosine phosphatase inhibitors and methods of use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This invention relates to the field of protein tyrosine phosphatase inhibition. BACKGROUND OF THE INVENTION This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B. Reversible protein tyrosine phosphorylation, coordinated by the

Protein tyrosine phosphatase inhibitors and methods of use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Modified phosphatases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis,

Regulation of human protein phosphatase IIc-like enzyme

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

TECHNICAL FIELD OF THE INVENTION The invention relates to the regulation of human protein phosphatase IIC-like enzyme activity for therapeutic effects. BACKGROUND OF THE INVENTION The protein phosphorylation/dephosphorylation cycle is one of the major regulatory mechanisms employed by eukaryotic

Methods of using thiazolidine derivatives to treat cancer or inflammation

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This invention is directed to methods of using thiazolidine derivatives to treat cancer or inflammation in a mammal. BACKGROUND OF THE INVENTION Protein tyrosine phosphorylation is an important mechanism for transmitting extracellular stimuli in biochemical and cellular events

Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to novel phosphotetrahydropyran compounds, primarily derivatives of mannose-6-phosphate, and their use in treating diseases or disorders that are mediated at least in part by T lymphocyte emigration from

Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION This invention relates to a biocompatible, non-inflammatory, collagen conjugate material, described herein in the form of a porous membrane structure, and to a process for making this material. While individual components of this system are known in the art and in the

1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their

Methods for decreasing set in inhibiting protein phosphatase 2A (PP2A) and/or increasing the activity of cyclin-dependent kinase 5 (CDK5) by an APOE peptide

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention provides methods for modulating SET activity by contacting SET with a binding agent. In one embodiment, the binding agent is an ApoE peptide derivative. The invention provides methods for the treatment of inflammatory and neurological conditions by

Modulation of biological signal transduction by RNA interference

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION 1. Technical Field The present invention relates generally to compositions and methods useful for treating conditions associated with defects in cell proliferation, cell differentiation, and cell survival. The invention is more particularly related to double-stranded RNA

Modulation of PTPRA to treat arthritis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Fibroblast-like synoviocytes (FLS) in the intimal lining of the joint synovium control the composition of the synovial fluid and extracellular matrix (ECM) of the joint lining. In rheumatoid arthritis (RA), FLS become aggressive and invasive, contributing to many aspects of RA pathology.

Treating post-seizure patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION The field of the invention is treating post-seizure patients to interfere with epileptogenesis. The highest incidence of seizures during lifetime is found in the neonatal period and neonatal seizures lead to a propensity for epilepsy and long-term cognitive deficits. Here

Constrained tricyclic sulfonamides

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The invention relates to the use of tricyclic chemical modulators of PPA2 and FOXO transcription factor proteins to treat cancer, proteotoxicity induced neurodegeneration, stress-induced depression, inflammation, acne, and viral infections. BACKGROUND Protein kinases have

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye